Becton Dickinson & Co. (NYSE:BDX) shares picked up nearly 3% today and hit a new 52-week high after the medical products maker reported a nearly 138% top-line gain during its fiscal 1st quarter, crushing Wall Street analysts’ forecasts along the way.
becton dickinson
Ivantis reels in $27M Series B round | Wall Street Beat
Ivantis said it raised a $27 million Series B round led by Ascension Health Ventures aimed at funding a quartet of clinical trials for its Hydrus Microstent glaucoma treatment.
The Irvine, Calif.-based medical device company said the device, an eyelash-sized stent, is designed to reduce eye pressure.
Former Kinetic Concepts CEO joins board at Becton Dickinson | Personnel Moves
BlackRock boosts medical device stakes
BlackRock Inc., 1 of the world’s largest hedge funds, boosted its stake in a clutch of medical device companies, with 1 exception.
Stryker taps new medical chief
Stryker (NYSE:SYK) tapped Dr. Scott Bruder, a Becton Dickinson & Co. (NYSE:BDX) veteran, to fill its newly created chief medical & scientific officer position.
Becton Dickinson closes Safety Syringes buyout
Becton Dickinson & Co. (NYSE:BDX) sealed the deal with privately-held Safety Syringes Inc., maker of developing anti-needlestick devices for prefilled syringes.
The merger, the terms of which were not disclosed, is expected to expand on Becton’s healthcare worker safety technologies for prefilled syringe customers, according to the company.
Becton, Dickinson settles Gen-Probe beef
St. Jude shares hit new low following FDA report | MassDevice.com On Call
MASSDEVICE ON CALL — Medical device maker St. Jude Medical’s (NYSE:STJ) shares lost more than 10% in one day after the FDA released a report detailing potential issues with the tech giant’s Durata pacemaker leads.
Becton Dickinson to close the books on a $45 million antitrust lawsuit
Healthcare giant Becton Dickinson & Co. (NYSE:BDX) may finally close the books on a years-long lawsuit after a New Jersey judge authorized a $45 million settlement to the company’s hypodermic product purchasers.
Will HHS Secretary Sebelius stay a 2nd term? | Personnel Moves
HHS’s Sebelius may stay for another term
Human Services Secretary Kathleen Sebelius might stay for a 2nd term, which would be unusual for someone in that position, according to a Kaiser Health News report.
Becton Dickinson expects medtech tax to cut 3% from next year’s bottom line
Becton Dickinson & Co. (NYSE:BDX) is expecting the medical device tax to cut about 3% off of its 2013 earnings growth, chairman, president & CEO Vincent Forlenza said during an earnings call this week.